We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Increased Microcirculation for Preventing Postoperative Wound Infections in Patients Undergoing Reduction Mammoplasty

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01538173
First Posted: February 23, 2012
Last Update Posted: December 2, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Rostock
Information provided by (Responsible Party):
Max Dieterich, University of Rostock
  Purpose
In this prospective study we investigated the impact of an improved postoperative microcirculation and its effect of surgical side infections after breast reduction.

Condition Intervention Phase
Surgical Side Infections After Breast Reduction Drug: 250ml HES 6% Drug: 9% NaCl 500ml Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Prospective Study Investigating the Role of Increased Microcirculation for Preventing Postoperative Surgical Side Infections in Patients Undergoing Reduction Mammoplasty

Resource links provided by NLM:


Further study details as provided by Max Dieterich, University of Rostock:

Primary Outcome Measures:
  • Surgical side infection [ Time Frame: 4 weeks ]
    Primary end point was the development of surgical side infection


Secondary Outcome Measures:
  • Risk factors [ Time Frame: 4 weeks ]
    Secondary endpoints were identification of possible risk factors for surgical side infections and nipple necrosis after breast reduction.


Enrollment: 334
Study Start Date: January 2007
Study Completion Date: February 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HES group
Application of twice a day 250ml HES 6% for three days postoperatively.
Drug: 250ml HES 6%
Application twice a day 250ml HES 6% for three days postoperatively.
Active Comparator: NaCl group
Application twice a day 500ml 9% NaCl for three days postoperatively.
Drug: 9% NaCl 500ml
Application twice a day 500ml 9% NaCl for three days postoperatively.

Detailed Description:
Many studies identifying risk factors for surgical side infections (SSI) after breast surgery included a large percentage of breast conserving therapies and risk factors for patients undergoing more extensive procedures like breast reduction (BR) are underrepresented and risk factors for more extensive breast surgeries might not be identified. Our approach to decrease SSI after BR was the application of an i.v. isotonic crystalloid solution, 6% hydroxyethylstaerke (HES) as a diminished peripheral blood flow and impaired vasculogenesis are characteristics of poorly healing wounds. HES causes a medium- to long-term increase in blood volume, blood flow and improved blood oxygen transport. Blood flow and tissue oxygenation are parts of regulating the healing process by utilizing molecular oxygen as a terminal oxidant. This antioxidant capacity can influence the wound healing process positively, as a characteristic feature of the inflammatory phase is the oxidative burst. HES additionally decreases haematocrite, blood viscosity and aggregation of erythrocytes positively influencing the complex components regulating wound healing. These characteristics and the increase in blood circulation might influence the postoperative healing and regeneration process.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Eligible patients were at least 18 years of age, scheduled for breast reduction, guaranteed follow-up of 30 days.

Exclusion Criteria:

  • Patients were excluded if they had a history of coagulopathy or history of antiplatelet agent use within 10 days of surgery
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01538173


Locations
Germany
University of Rostock, Department of Obstetrics and Gynecology
Rostock, MV, Germany, 18059
Sponsors and Collaborators
Max Dieterich
University of Rostock
Investigators
Principal Investigator: Max Dieterich, MD University of Rostock
  More Information

Responsible Party: Max Dieterich, Principle investigator, University of Rostock
ClinicalTrials.gov Identifier: NCT01538173     History of Changes
Other Study ID Numbers: BR02
First Submitted: February 19, 2012
First Posted: February 23, 2012
Last Update Posted: December 2, 2015
Last Verified: November 2015

Keywords provided by Max Dieterich, University of Rostock:
surgical side infection
breast reduction
reduction mammaplasty
prospective trial
microcirculation
breast surgery

Additional relevant MeSH terms:
Infection
Communicable Diseases